A conversation with Dave Gulezian (see bio), President and CEO of Viscira, about the use of virtual reality simulation to reach and teach physicians at medical conventions. Featured is his company's "EyeMAC" Wet AMD virtual simulation exhibit.
Aired LIVE on:
Thursday, March 11, 2010
Click the play button in the widget above to begin listening to this podcast.
This show and ALL Pharma Marketing Talk shows are available as podcasts via PMT on iTunes (FREE!).
The traditional way of communicating info to professionals -- brochures, print advertisements, and journal articles -- has become stagnant. Industry is moving towards a new communications model using the Internet and new media. Information is delivered using a more interactive, hands-on approach. The use of technology solutions provides lower cost and more streamlined distribution channels.
Viscira's Wet AMD virtual simulation exhibit helped a leading biotech company attract attention to its booth providing quality opportunities for sales reps to interact with target healthcare professionals. This is just one example of Viscira's innovative, cutting edge product solutions.
Some Questions/Topics Discussed
Tell us about "EyeMAC" - the virtual reality technology, why it was needed, where it was deployed.
How many physicians viewed the program and what did they think of it?
How does this help pharma marketers? Do you think this kind of program would help market products that treat other conditions? What are the benefits of these solutions for physicians/patients?
How do current trends regarding the role of the field sales force effect a company like Viscira?
Dave Gulezian: As founder of Viscira, Dave brings more than 12 years of executive management experience with innovative, technology-based companies, including the last 8 within the life sciences industry. He has personally closed and managed major interactive software and new-media programs with many of the market leaders in the pharmaceutical and biotech industries, including Amgen, Novartis, Pfizer, Genentech, Abbott Labs, Merck, Roche and Takeda Pharmaceuticals. Dave has a BS in Electrical Engineering from Cornell University and an MBA from Stanford University's Graduate School of Business.